A Classification of the Tumors of the Glioma Group on a Histogenetic Basis with a Correlation Study of Prognosis. Philadelphia: Lippincott, 1926., .
The glia identity of neural stem cells. Nature Neurosci 2003; 6: 1127–34..
Neural stem cells and neurooncology: Quo vadis?J Cell Biochem 2003; 88: 11–9., , .
Molecular pathology of malignant gliomas. AnnuRev Pathol Mech Dis 2006; 1: 97–117..
Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105–11., , , .
A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997; 7: 755–64..
Brain Tumor Pathology: Current Diagnostic Hotspots and Pitfalls. Dordrecht, The Netherlands: Springer, 2006..
Biochemistry of apoptosis. Nature 2002; 2000: 770–6..
Mechanisms of apoptosis in central nervous system tumors: application to theory. Curr Neurol Neurosci Rep 2002; 2: 246–53., .
Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion. J Neurol Sci 2003; 216: 1–10., , , .
Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 1988; 68: 698–704., , , .
Changes in proliferating cell nuclear antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory. Neurosurgery 1994; 35: 1036–45., , , , , .
Cell proliferation and invasion in malignant gliomas. Anticancer Res 1997; 17: 61–70., , , .
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 2007; 114: 97–109., , , , , , et al.
Preferential brain locations of low-grade gliomas. Cancer 2004; 100: 2622–6., .
Oligodendroglioma. Part I: Pattern of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neuro-Oncology 1997; 34: 37–59., , , , , .
Oligodenrogliomas. Part II: A new grading system based on morphological and imaging criteria. J. Neuro-Oncology 1997; 95: 493–504., , , , , , et al.
What's an oligodendroglioma?Brain Pathol 2002; 12: 257–9..
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473–9., , , , , , et al.
Prognostic factors in oligodendroglioma. Can J Neurol Sci 1997; 24: 313–9., , , , , , et al.
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97–109., , , , , , et al.
Role of apoptosis in the prognosis of oligodendrogliomas. Neurochem Int 1997; 2: 245–50., , , , , .
The relation of oligodendrocytes and astrocytes in cerebral tumors. J Pathol Bacteriol 1935; 41: 259–66..
Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol 2002; 52: 842–5., , , , , , et al.
Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995; 54: 91–4., , , , , , et al.
Primary and secondary glioblastoma: from concept to clinical diagnosis. Neuro-Oncology 1999; 1: 44–51., .
Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro-Oncology 2007; 9: 424–9., , , , .
Grading of astrocytomas: a simple and reproducible method. Cancer 1988; 62: 2152–65., , , .
Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 1999; 45: 923–9., , , , , , et al.
2007 Nov 9 [Epub ahead of print]., , , , , , et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro-Oncology,
Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 2000; 54: 1442–8., , .
Gliomas: classification with MR imaging. Radiology 1990; 174: 411–5., , , , , , et al.
Use of a neural network and a multiple regression model to predict histologic grade of astrocytoma from MRI appearances. Neuroradiology 1995; 37: 89–93., , , .
MR imaging of adult supratentorial astrocytomas: an attempt of semiautomatic grading. Radiat Med 1995; 13: 5–9., , , , .
Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 1989; 172: 541–8., , , , , , et al.
Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990; 177: 633–41., , , , , , et al.
Localized 1H NMR spectroscopy in fifty cases of newly diagnosed intracranial tumors. J Comput Assist Tomogr 1991; 15: 67–76., , , , , , et al.
Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992; 185: 675–86., , , , , , et al.
Studies of human tumors by MRS: a review. NMR Biomed 1992; 5: 303–24..
Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996; 2: 323–5., , , , , , et al.
Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 2000; 42: 333–8., , , , , .
A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images. Nat Med 2000; 6: 1287–9., , , , , , et al.
Choline phospholipid metabolism: a target in cancer cells?J Cell Biochem 2003; 90: 525–33., , .
Tumour phospholipid metabolism. NMR Biomed 1999; 12: 413–39..
Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. Am J Neuroradiol 2000; 21: 659–65., , , .
Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. J Neuro-oncol 2007 Dec 28 [Epub ahead of print]., , , , , , et al.
Response of non-Hodgkin lymphoma to radiation therapy: early and long-term assessment with H-1 MR spectroscopic imaging. Radiology 1995; 194: 271–6., , , , , , et al.
Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res 1996; 56: 4630–5., , , , .
Choline-containing compounds in human astrocytomas studied by 1H NMR spectroscopy in vivo and in vitro. J Neurochem 1994; 63: 1538–43., , , .
Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000; 50: 215–26., , , , , , et al.
Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997; 87: 516–24., , , , , , et al.
Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006; 238: 958–69., , , , , , et al.
Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg 2003; 98: 269–76., , , , , , et al.
1H MR spectroscopy detection of lipids and lactate in metastatic brain tumors. NMR Biomed 1996; 9: 65–71., , , , .
Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. Am J Neuroradiol 1995; 16: 1593–603., , , , , .
1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 1994; 7: 149–55., , , .
Correlation between the occurrence of 1H-MRS lipid signal, necrosis and lipid droplets during C6 rat glioma development. NMR Biomed 2003; 16: 199–212., , , , , .
Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett 2003; 342: 163–6., , , , , , et al.
On the origin of cancer cells. Science 1956; 123: 309–14..
New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma. Eur Radiol 2008; 12: 2901–11., , , , , , et al.
Single voxel proton MR spectroscopy findings of typical and atypical intracranial meningiomas. Eur J Radiol 2006; 60: 48–55., , , , .
Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging 2002; 16: 229–37., , , , .
Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995; 38: 901–09., , , , , .
In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging. Ann Neurol 1998; 44: 273–8., , , , , .
Late-onset sporadic ataxia, pontine lesion, and retroperitoneal fibrosis: a case of Erdheim–Chester disease. Neurol Sci 2008; 29: 263–7., , , , , , et al.
High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002; 222: 715–21., , , , , .
Necrotic tumor versus brain abscess: importance of amino acids detected at 1H MR spectroscopy – initial results. Radiology 1999; 213: 785–93., , , , , , et al.
The role of proton magnetic resonance spectroscopy in the diagnosis and categorization of cerebral abscesses. Neurosurg Focus 2008; 24: E7., , .
Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 2003; 24: 1989–98., , , , , , et al.
Noninvasive magnetic resonance spectroscopic imaging biomarkers to predict the clinical grade of pediatric brain tumors. Clin Cancer Res 2004; 10: 8220–8., , , , , , et al.
Brain tumor classification based on long echo proton MRS signals. Artif Intell Med 2004; 31: 73–89., , , , , , et al.
Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology 2008; 50: 759–67., , , , , , et al.
Predicting survival of children with CNS tumors using proton magnetic resonance spectroscopic imaging biomarkers. Int J Oncol 2007; 30: 651–7., , , , , , et al.
Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 2000; 18: 1020–6., , , , , , et al.
Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med 2003; 49: 29–36., , , , , .
Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg 2003; 98: 74–81., , , , , , et al.
Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain leisons in adults?Am J Neuroradiol 2008; 29: 366–72., , , , , .
Intraaxial brain masses: MR imaging-based diagnostic strategy – initial experience. Radiology 2007; 243: 539–50., , , , , , et al.
Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. Am J Neuroradiol 2001; 22: 604–12., , , , , , et al.
Integration of biochemical images of a tumor into frameless stereotaxy achieved using a magnetic resonance imaging/magnetic resonance spectroscopy hybrid data set. J Neurosurg 2004; 101: 287–94., , , , , .
MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 2001; 50: 915–28., , , , , , et al.
Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996; 36: 1251–61., , , , , , et al.
Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology 2002; 44: 216–22., , , , , , et al.
Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002; 51: 912–9; discussion 919–20., , , , , , et al.
Magnetic resonance spectroscopy guided brain tumor resection: differentiation between recurrent glioma and radiation change in two diagnostically difficult cases. Can J Neurol Sci 1998; 25: 13–22., , , , , .
Proton MR spectroscopy of pediatric cerebellar tumors. Am J Neuroradiol 1995; 16: 1821–33., , , , , , et al.
Untreated pediatric primitive neuroectodermal tumor in vivo: quantitation of taurine with MR spectroscopy. Radiology 2005; 236: 1020–5., , , , , , et al.
Prognostic value of proton MR spectroscopy of cerebral hemisphere tumors in children. Neuroradiology 1998; 40: 121–5., , , , , ., et al.